Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
April 2025 | Volume 24 | Issue 4 | 413 | Copyright April 2025 Published online March 7, 2025 doi:10.36849/JDD.8605 Sophia Daniel BS a,b , Stephanie Waggett BS a,c , Elliott Lyles BS a , Pelin Sagut MD a,d , Parisa Shamaei Zadeh MSPH b , Anthony Marcelletti BHS b , Carol Stegura ME c , Lara Wine Lee MD PhD d a College of Graduate Studies, Medical University of South Carolina, Charleston, SC b College of Medicine, University of Kentucky, Lexington, KY c College of Medicine, Medical University of South Carolina, Charleston, SC d Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC Abstract Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss
J.WangP
With sign-off from dermatologists and aestheticians, this radiance-enhancing resurfacer can work as a mask, scrub, and peel based on application
These injectable medications, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), were developed primarily for diabetes management but have demonstrated broader cardiovascular advantages
Received 2022-7-15
